What is bioavailability? Philosophy of bioavailability testing

Area of Science:

• Pharmacokinetics
• Clinical Pharmacology
• Drug Development

Background:

• Bioavailability is frequently considered a key indicator of clinical effectiveness.
• Regulatory bodies like the FDA accept pharmacologic responses and clinical outcomes as measures of bioavailability.
• Current bioavailability studies predominantly utilize blood concentration or urinary excretion data.

Purpose of the Study:

• To critically evaluate the reliance on blood and urine data for assessing bioavailability.
• To highlight the limitations of pharmacokinetic data in predicting clinical effectiveness.
• To discuss the challenges in evaluating raw data using pharmacokinetic methods.

Main Methods:

• Review of existing bioavailability study methodologies.
• Analysis of the relationship between pharmacokinetic parameters and clinical outcomes.
• Exploration of factors influencing drug absorption and their impact on bioavailability assessment.

Main Results:

• Blood and urinary excretion data do not inherently represent clinical effectiveness without explicit correlation.
• Clinical effectiveness is influenced by numerous complex variables including disease state, nutrition, food intake, and patient-specific factors.
• Bioavailability tests, when based on limited data, function primarily as biologic quality control under specific conditions.

Conclusions:

• The direct extrapolation of bioavailability data from blood or urine levels to clinical effectiveness is scientifically questionable.
• A comprehensive approach is needed to assess drug efficacy, considering individual patient variability and multifactorial influences.
• Pharmacokinetic data evaluation requires careful consideration of its limitations in predicting real-world clinical performance.